Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – Medical Xpress
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine.
The NEOSTAR…
-
General23 hours agoNRLW Sunday: Brisbane Broncos hammer Newcastle Knights, Cronulla Sharks move to third on ladder
-
General15 hours agoFirst home buyers score early access to deposit scheme
-
Noosa News13 hours agoForum responds to urgent homelessness issues in Nambour
-
General12 hours agoEnergy provider ENGIE to ‘correct’ electricity bills for thousands of South Australian customers